Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Survey rates meth number one

This article was originally published in The Tan Sheet

Executive Summary

Sens. Jim Talent (R-Mo.) and Dianne Feinstein (D-Calif.) cite findings from a recent law enforcement survey identifying methamphetamine as the number one problem in the majority of U.S. counties to urge the Senate to pass their anti-meth legislation. According to the survey of 500 law enforcement agencies, meth-related arrests increased 87% over the past three years. Respondents also cited meth as the leading drug-related problem in the country. The Talent/Feinstein bill would create a national policy concerning pseudoephedrine cold products and mandate the products' placement behind the counter, as well as limit purchases of the meth-precursor to 7.5 g per month. The Senate Subcommittee on the Judiciary may mark up the bill during its next meeting tentatively scheduled for July 14...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098410

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel